Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:atccode |
L01 XX32
|
| gptkbp:brand |
gptkb:Zydelig
|
| gptkbp:casnumber |
870281-82-6
|
| gptkbp:chemical_formula |
C22 H23 Cl N2 O4 S
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:clinical_use |
combination therapy
monotherapy |
| gptkbp:contraindication |
active infections
severe hepatic impairment |
| gptkbp:discovered_by |
gptkb:Gilead_Sciences
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosage_form |
150 mg twice daily
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:effective_date |
marketed
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Idelalisib
|
| gptkbp:indication |
relapsed or refractory CLL
relapsed follicular B-cell non-Hodgkin lymphoma |
| gptkbp:lifespan |
approximately 8 hours
|
| gptkbp:marketed_as |
gptkb:Gilead_Sciences
|
| gptkbp:mechanism_of_action |
PI3 K inhibitor
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:monitors |
0 A2 D1 B2 D1 A
|
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
oral bioavailability
protein binding inhibits cell proliferation induces apoptosis metabolized by liver enzymes |
| gptkbp:research_status |
ongoing clinical trials
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
monitor blood counts
monitor liver function monitor for infections |
| gptkbp:side_effect |
gptkb:anemia
fatigue nausea abdominal pain vomiting diarrhea rash thrombocytopenia hepatotoxicity neutropenia pneumonitis hypersensitivity reactions |
| gptkbp:targets |
PI3 K delta
|
| gptkbp:used_for |
gptkb:Oncology
follicular lymphoma |
| gptkbp:weight |
438.94 g/mol
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|